Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

06 sept. 2017 07h01 HE | Source: Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy: Interim Results for the six months ended 30 June 2017

Faron Pharmaceuticals Ltd("Faron" or the "Company") Interim Results for the six months ended 30 June 2017 INTEREST Phase III Traumakine® trial patient recruitment to complete in Q4 2017...
04 sept. 2017 07h12 HE | Source: Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy: Faron announces that US FDA proposes proceeding directly to BLA submission for Traumakine® following completion of European and Japanese Phase III studies

Faron Pharmaceuticals Ltd("Faron" or the "Company") Faron announces that US FDA proposes proceeding directly to BLA submission for Traumakine® following completion of European and Japanese Phase...
29 mars 2017 11h13 HE | Source: Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy: Final Results for the year ended 31 December 2016

Faron Pharmaceuticals Ltd("Faron" or the "Company") Final Results for the year ended 31 December 2016 TURKU - FINLAND, 29 March 2017 Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the...